Saturday 17 October 2026 Export VALN’s income statement to Excel — free account

Valneva SE Sponsored ADR

In the quarter to June 2026, revenue fell 17.3%, EPS fell 222.1%, free cash flow fell 56.1% and total debt rose 12.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

5.61 0.30 −5.08%

Follow VALN

Alert me

Market cap: $560.4M
P/E: 59.7×
Fwd P/E: 19.4×
Dividend yield: —
F-score: 2/9
Altman Z: −0.49
Beneish M: −3.28
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 560.39

Revenue 164.10

Net Income (163.66)

Free Cash Flow (58.90)

Net Debt 72.71

Current Ratio 2.16

Debt/Equity 2.27

P/E ratio 59.68

Fwd P/E 19.40

P/S ratio 3.05

P/B ratio 5.30

Past 5Y EPS Growth —

This Y EPS Growth 34.68%

Next Y EPS Growth 161.40%

Next Y revenue growth 1,162.90%

Next 5Y EPS Growth 58.87%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 40.07%

10-year low 10-year high

P/B against its own 10 years 66.72%

10-year low 10-year high

EV/Sales against its own 10 years 49.49%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	136	182	124	141
Receivables	45	38	31	19
Inventory	48	58	57	56
Other	55	45	39	41
	284	324	252	259

	2023	2024	2025	Q'26
Payables	48	38	28	27
ST’ Debt	48	23	20	21
Other	55	37	32	44
	172	124	106	120

Compound Annual Growth %

	10y	5y	3y
Sales	—	9.41%	(19.63%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	6.31%	(19.65%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	36	—	—	—	—
’25	52	—	—	—	198
’24	36	—	—	—	184
’23	36	44	41	—	166
’22	25	74	152	119	381
’21	28	29	26	—	412
’20	39	14	13	64	126

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	(16)	—	—	—
’25	(9)	(4)	(33)	—	(60)
’24	(31)	(40)	(84)	—	(73)
’23	(26)	(47)	(149)	—	(219)
’22	(30)	(79)	(89)	(62)	(258)
’21	57	43	(59)	—	91
’20	3	122	(44)	157	157

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(16)	—	—	—
’25	(10)	(5)	(37)	—	(65)
’24	63	(139)	(106)	—	(90)
’23	(30)	(51)	(154)	—	(235)
’22	(41)	(85)	(112)	(62)	(289)
’21	37	16	(59)	—	(19)
’20	3	122	(44)	136	135

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.42)	—	—	—	—
’25	(0.13)	—	—	—	(1.54)
’24	0.89	—	—	—	(0.17)
’23	(0.28)	(0.13)	(0.27)	—	(1.57)
’22	(0.54)	(1.40)	0.60	(0.34)	(2.61)
’21	(0.72)	(0.73)	(1.86)	—	(1.77)
’20	(0.01)	(0.30)	(0.47)	(0.02)	(1.62)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	24.16	9.77	9.07	3.62	4.20	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	67.84	53.11	17.05	10.76	12.25
People
People	Employees	—	—	—	—	640	762	719	676	713	674
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.20	0.54	0.53	0.25	0.26	0.29
Income, $m
Income, $m	Revenue	99	127	130	142	126	412	381	166	184	198
	Gross margin, %	44.92	48.19	57.87	56.87	50.78	46.01	10.20	34.37	41.89	38.66
	EBT	(51)	(15)	3	(10)	(75)	(83)	(153)	(107)	(12)	(129)
	EBT margin, %	(51.91)	(11.93)	1.97	(6.94)	(59.19)	(20.10)	(40.08)	(64.16)	(6.77)	(65.34)
	Net income	(52)	0	4	(2)	(74)	(87)	(151)	(110)	(13)	(130)
	Depreciation	12	13	8	10	11	17	22	19	21	25
Per share, $
Per share, $	Revenue	2.44	2.31	3.23	3.09	2.78	8.44	6.59	2.40	2.52	2.35
	Earnings	(0.69)	(0.18)	0.05	(0.02)	(1.62)	(1.77)	(2.61)	(1.57)	(0.17)	(1.54)
	Cash flow	(0.03)	0.17	0.35	0.08	3.47	1.86	(4.48)	(3.17)	(1.00)	(0.71)
	Capex	0.00	0.00	0.00	0.00	(0.49)	(2.26)	(0.53)	(0.22)	(0.24)	(0.06)
	Free cash flow	(0.03)	0.17	0.35	0.08	2.98	(0.39)	(5.01)	(3.39)	(1.24)	(0.77)
	Book value	2.59	2.03	4.09	3.31	1.95	4.13	4.01	2.00	2.69	1.43
	Shares, m	41	55	40	46	45	49	58	69	73	84
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	18.71	22.99
	P/S	10.28	10.28	10.28	10.28	10.28	22.34	2.55	2.98	1.97	3.95
	P/B	19.32	19.32	19.32	19.32	19.32	35.66	4.03	4.14	1.28	3.86
	EV/Sales	8.44	8.44	8.44	8.44	8.44	20.57	2.16	2.84	2.08	4.12
	EV/FCF	3.41	3.41	3.41	3.41	3.41	15.14	(2.43)	(2.12)	(0.96)	(4.45)
Cash, $m
Cash, $m	Operating cash flow	(1)	10	14	3	157	91	(258)	(219)	(73)	(60)
	Capex	(4)	(5)	(4)	(12)	(22)	(110)	(31)	(15)	(18)	(5)
	Free cash flow	(1)	10	14	3	135	(19)	(289)	(235)	(90)	(65)
Balance, $m
Balance, $m	Working capital	55	55	95	99	151	257	155	113	200	146
	Total debt	87	86	66	96	61	68	104	191	203	203
	Net debt	42	40	(28)	23	(173)	(342)	(201)	55	21	79
	Shareholders’ equity	105	112	165	152	88	202	232	139	196	120
Returns, %
Returns, %	ROA	(23.22)	(12.70)	1.52	(0.67)	(17.92)	(11.74)	(18.62)	(19.05)	(2.55)	(26.27)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	(243.03)	(28.66)	4.16	(29.19)
	ROE	(47.72)	(12.75)	2.72	(1.24)	(61.22)	(59.86)	(69.66)	(59.28)	(7.91)	(82.42)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CRMD CorMedix Inc	$581.5M	3.0×	16.5×	+156.52% (above 0%: growing)	+13.79% (above 0%: growing)	+185.90% (above 0%: growing)	75.66%	42.10%	Compare
SLN Silence Therapeutics PLC Sponsored ADR	$581.1M	— (loss-making)	— (loss-making)	+197.18% (above 0%: growing)	n/m	+106.95% (above 0%: growing)	97.39%	0.00%	Compare
SGMT Sagimet Biosciences Inc.	$574.7M	— (loss-making)	— (loss-making)	—	n/m	−21.95% (below 0%: shrinking)	100.00%	0.00%	Compare
DBVT DBV Technologies S.A.	$572.6M	— (loss-making)	—	−53.33% (below 0%: shrinking)	n/m	−56.15% (below 0%: shrinking)	100.00%	(7,228.57%)	Compare
VALN Valneva SE Sponsored ADR	$560.4M	59.7×	19.4×	−17.29% (below 0%: shrinking)	n/m	−56.05% (below 0%: shrinking)	15.29%	(76.67%)
STTK Shattuck Labs, Inc.	$555.0M	— (loss-making)	— (loss-making)	−10.31% (below 0%: shrinking)	n/m	+1.01% (above 0%: growing)	100.00%	0.00%	Compare
VECT VectivBio Holding AG	$545.5M	— (loss-making)	— (loss-making)	—	n/m	—	91.93%	0.00%	Compare
PBYI Puma Biotechnology, Inc.	$543.0M	18.2×	24.2×	+7.75% (above 0%: growing)	+33.33% (above 0%: growing)	−88.45% (below 0%: shrinking)	77.92%	13.42%	Compare
DRUG Bright Minds Biosciences Inc.	$534.7M	— (loss-making)	—	—	n/m	−124.63% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$563.8M	—	—	+7.75%	—	−21.95%	94.66%	0.00%

All 614 Biotechnology stocks →

Valneva SE Sponsored ADR (VALN) key facts

Valneva SE Sponsored ADR (VALN) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, VALN traded at $5.61, a market capitalization of $560.4 million.
Return on equity was −82.4% and debt-to-equity 2.27.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −0.49 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.